This agrees with the literature: CD4+ T cells primarily mediate anti-tumor immunity and are associated with favorable prognosis in lung cancer patients [72–74]; B cells also show anti-tumor functions in all stages of human lung cancer development and play an essential role in anti-tumor responses [75, 76]. This evidence concerns the gene CD4 and lung cancer.